Chemoprevention of Prostate Carcinoma - A Plea

The document discussed the challenges of diagnosing and treating prostate cancer, particularly due to its high prevalence, tendency to occur in older age, slow progression, and high treatment costs. It highlighted the potential of chemoprevention as a solution, citing two randomized, controlled studies that demonstrated the effectiveness of 5α-reductase inhibitors (finasteride, dutasteride) in preventing prostate cancer. Additionally, there was growing evidence for the efficacy of other compounds such as selective estrogen receptor modulators (SERMs), NSAIDs, and statins. The review examined the risks and benefits of chemoprevention, including health economic considerations, and concluded that these options should be explored openly and without bias.